How Moderna's Latest Numbers Set the Stage for Its Next Chapter

Moderna (MRNA) has just posted third quarter FY 2025 revenue of US$1,016 million with a basic EPS loss of US$0.51 and net income loss of US$200 million, as its mRNA platform continues to move through an investment heavy phase. The company has seen quarterly revenue move from US$966 million in Q4 2024 to US$108 million in Q1 2025, US$142 million in Q2 2025 and then US$1,016 million in Q3 2025. Over the same stretch, basic EPS shifted from a loss of US$2.91 to losses of US$2.52, US$2.13 and US$0.51. For investors, the picture is one of pressured margins alongside a growing late stage pipeline, which puts the focus firmly on how quickly that R&D spend can translate into more sustainable profitability.

With the headline figures on the table, the next step is to see how these results line up with the major bullish and bearish narratives around Moderna to understand which stories the numbers back up and which they call into question.

Loss narrows to US$200 million as quarterly profile shifts

• Net income loss in Q3 2025 was US$200 million, compared with losses of US$971 million in Q1 2025 and US$825 million in Q2 2025, while trailing twelve month net income loss sits at US$3.1b on US$2.2b of revenue.
• Bulls point to this narrower quarterly loss as early support for their view that margins can improve, yet the trailing twelve month loss of US$3.1b and a five year loss growth rate of about 50.1% a year keep the bearish concern about persistent unprofitability very much in play.
  • Optimistic investors focus on the Q3 loss being much smaller than the prior quarters in 2025, while critics highlight that forecasts still expect the company to remain unprofitable over the next three years.
  • This tension between a single quarter showing a smaller loss and a longer track record of widening losses is exactly what both sides will keep watching in future updates.

If you want to see how bullish investors connect this margin story to their longer term view on the business, have a look at the 🐂 Moderna Bull Case

Pipeline depth vs current cash burn

• Across the first three quarters of 2025, Moderna reported 9 products in Phase I, 18 in Phase II and between 6 and 9 in Phase III, while the latest quarter still came with a basic EPS loss of about US$0.51 and trailing twelve month EPS of about US$8.04 loss.
• Consensus narrative often leans on this broad late stage pipeline and cost reduction plans as support for future earnings potential, yet the data here shows that a sizeable development portfolio currently sits alongside large trailing losses, so the key question for both bulls and bears is how many of these programs can eventually offset that cash burn.
  • Supporters point to multiple Phase III programs as a foundation for future products, while skeptics link the US$3.1b trailing loss to the risk that not enough of these candidates reach approval to change the earnings profile.
  • For you as an investor, it means the pipeline is clearly sizable, but today it still shows up mainly as R&D expense and not yet as diversified revenue.

P/S of 7.4x with DCF fair value below market price

• The shares trade on a P/S of 7.4x versus a peer average of 7.5x and a US Biotechs industry average of 11.3x, while the current share price of US$42.23 sits above a DCF fair value of about US$38.19 and below the single allowed analyst price target reference of US$39.00.
• Bears argue that ongoing losses and recent share price volatility make it hard to justify paying more than DCF fair value, even if P/S looks slightly cheaper than peers.
  • That caution leans on the combination of a US$3.1b trailing loss and a share price that is above the DCF fair value, which together suggest limited room for error in how the story plays out.
  • At the same time, the P/S being a touch below peers and well below the broader biotech group is what more optimistic investors point to when they argue the market may already be pricing in many of these risks.

If you want to see how more cautious investors frame these valuation tensions around the current numbers, take a look at the 🐻 Moderna Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Moderna on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

See the numbers differently? Take a couple of minutes to test your own view against the data and shape a narrative that fits your thesis: Do it your way

A great starting point for your Moderna research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision.

See What Else Is Out There

Moderna is still posting sizeable trailing twelve month losses of about US$3.1b on US$2.2b of revenue, with forecasts expecting continued unprofitability.

If that level of ongoing loss makes you want more resilient options, check out our 85 resilient stocks with low risk scores to quickly spot companies with steadier profiles and fewer financial shocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.